Allele and genotype frequency of CYP2C9 in Tamilnadu population
Authors:
- 1 November 2003
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (8-9) , 707-709
Abstract
To identify the frequency of CYP2C9*1, *2 and *3 alleles and the genotype of CYP2C9 gene in the Tamilian population. The study was conducted on 135 unrelated healthy human volunteers. DNA was extracted from the peripheral leukocytes samples and was analyzed using the polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) protocol. The PCR products were digested with AvaII, KpnI or NsiI restriction enzymes. The digested products were separated using 8% polyacrylamide gel and stained by ethidium bromide. Genotyping of the subjects was done based on DNA fragment size. The frequencies of CYP2C9*1, *2 and *3 alleles in the Tamilian population were 0.907, 0.026 and 0.067, respectively. The distribution of CYP2C9*1/*1, *1/*2, *1/*3 and *2/*3 genotypes were 0.823, 0.044, 0.126 and 0.007, respectively. CYP2C9*3 is the most frequent mutant allele found in the Tamilian population. The distribution of this mutant allele in the Tamilian population was found to be lesser than in Caucasians but higher than in Chinese.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugsThe American Journal of Medicine, 2002
- Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.2002
- Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2Clinical Pharmacology & Therapeutics, 2002
- Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizersPharmacogenetics, 2001
- Recent advances in P450 researchThe Pharmacogenomics Journal, 2001
- Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitisPharmacogenetics, 2000
- Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allelePharmacogenetics, 1999
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994